$CAMT

Aviram Lior sold $1.1M of CAMT

Aviram Lior sold 6,694 shares of CAMTEK LTD (CAMT) at an average of $168.43 ($162.00–$175.00, $1.13M total) across 4 trades over 2026-08-11 to 2026-08-12.

Original reporting
SEC EDGAR · Aviram Lior
Published Aug 13, 2026, 2:41 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 13, 2026, 2:44 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CAMT
Neutral
medium confidence
Mentioned
$CAMT
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CAMTNeutralLow
01

Why it matters

The newest disclosed fact is the director’s open-market sale size, price range, and post-transaction holdings. It may influence short-term sentiment but lacks accompanying fundamental catalysts.

02

Market read

Traders may monitor CAMT for any follow-through in volume or sentiment, but the filing alone is unlikely to drive a durable repricing.

03

What to watch

The article does not state whether the sale was tax-related, diversification-driven, or part of a broader compensation plan; also, no 10b5-1 plan is cited, which can cut both ways for interpretation.

Relevance 6/10Novelty 5/10Timing: filed 2026-08-13, covering sales on 2026-08-11 to 2026-08-12

Background

This is an SEC Form 4 insider transaction for CAMTEK, reported by director Aviram Lior.

Company-level read

Ticker impact

$CAMTNeutralMedium confidence
Context

CAMTEK director Aviram Lior sold $1.13M of CAMT shares in open-market trades at $162 to $175 during 2026-08-11 to 2026-08-12.

Expected impact

Likely limited, short-lived sentiment impact; any move would be small versus broader market drivers.

Evidence & confidence

Form 4 shows an open-market sale with no 10b5-1 plan stated, but it is not accompanied by new company guidance, contracts, or regulatory actions.

Market effects

No sector read-through is provided beyond a single insider sale.

None indicated.

None indicated.

Counterpoint

Insider sales can be routine liquidity events and may not signal reduced confidence, especially when spread across multiple trades.

Key entities

  • CAMTEK LTD

    Company whose shares were sold by a director via open-market transactions.

  • Aviram Lior

    CAMTEK director who sold 6,694 shares for about $1.13M.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CAMTMed

CAMTEK LTD (CAMT): Financial results for FY

CAMTEK LTD (CAMT) furnished an SEC Form 6-K — earnings release. Yes ☐ No ☒ SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. This Form 6-K, including all exhibits hereto, is hereby incorporated by r

$ESLTMed

Tue: Rate cut lifts market

The Tel Aviv Stock Exchange rose after the Bank of Israel cut interest rates to 3.25%. The Tel Aviv 35 Index gained 0.22%, while Dimri led gains with a 5.47% rise. OPC Energy fell 4.67%, the biggest decline. Key movers included Elbit Systems, Teva, and Ormat, which rose, and Camtek and Tower Semiconductor, which fell.

$CRDOMed

3 Under-the-Radar AI Stocks Wall Street Is Missing

Credo Technology (CRDO) reported Q4 2026 revenue of $437M, up 157% YoY, with guidance for 80% YoY growth in 2027. Astera Labs (ALAB) saw Q2 2026 revenue of $392.4M, up 104% YoY, with Scorpio X series ramping ahead of schedule. Camtek (CAMT) reported Q2 2026 revenue of $133.24M, up 8% YoY, with a strong order book extending into 2027.

$CAMTMedAI 8/10

Camtek (CAMT) Posted Record Q2 Revenue, Is The AI Upside Already Priced In?

Camtek (CAMT) reported record Q2 revenue of $600M+ year-to-date, driven by AI-related advanced packaging demand. The company issued upbeat Q3 guidance, contributing to a 17.55% monthly and 48.74% year-to-date stock price increase. Analysts debate its valuation, with some seeing it as 8.3% undervalued at $171.80, while others suggest it's overvalued based on discounted cash flow models.